Research programme: small molecule therapeutics - Genesis Therapeutics
Latest Information Update: 14 Feb 2024
At a glance
- Originator Genesis Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 12 Feb 2024 Early research in Unspecified in USA (unspecified route) prior to February 2024 (Genesis Therapeutics website, February 2024)